GO
Loading...

Mylan Inc

More

  • *Best Buy climbs after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. It's predicated on the fact that when you get up around new highs market participants tend to get a little vertigo, "said Art Hogan, chief market strategist at Wunderlich Securities in New York.

  • *Best Buy climbs in premarket after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. "The market is naturally settling in, taking a breather until the scales tip either way to commence the next move to continued to new heights or a consolidated pullback," said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • Mylan tops 4Q profit forecasts before move overseas Monday, 2 Mar 2015 | 4:36 PM ET

    Analysts expected $1.04 per share, according to Zacks Investment Research. As part of the $5.3 billion deal, Mylan relocated to the Netherlands in a tax-reducing move called a corporate inversion, changing its name to Mylan NV from Mylan Inc. Mylan is still keeping a U.S. headquarters in Canonsburg, Pennsylvania. Mylan said it expects to report adjusted net...

  • March 2- Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America. Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.

  • Watchdog group seeks FDA ban of antifungal tablets Tuesday, 24 Feb 2015 | 10:08 AM ET

    Public Citizen filed a petition Tuesday asking the FDA to ban ketoconazole tablets, which are used against hard-to-treat fungal infections. In July 2013 the FDA restricted ketoconazole's use to infections that do not respond to other drugs. Those findings were delivered at an agency workshop in January 2013, six months before the FDA decided to restrict the...

  • WASHINGTON, Feb 12- The Senate Finance Committee's top Democrat called corporate tax inversions a "virus" on Thursday, saying they threaten to spread unless Washington moves quickly to overhaul the U.S. tax code. Critics of the deals include Democratic President Barack Obama, whose administration moved to crack down on them in September by imposing new...

  • Insiders bail on stock market after earnings Wednesday, 11 Feb 2015 | 11:12 AM ET
    Traders on the floor of the New York Stock Exchange.

    Insider selling jumped in the last week as executives looked to cash in on their companies after earnings came out.

  • *Wave of inversion deals had many causes, experts say. *Earnings stripping, foreign profits seen as key. WASHINGTON, Feb 9- When a series of big U.S. companies last year moved to reincorporate abroad in inversion deals, some Republican lawmakers and tax policy critics blamed the high U.S. corporate tax rate.

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • Feb 2- Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of women's health products. Monday's announcement marks Mylan's second deal with an Indian drugmaker after it bought Bangalore- based Strides Arcolab's injectable drugs unit for...

  • Abbott Labs 2015 outlook in line with estimates Thursday, 29 Jan 2015 | 11:05 AM ET
    Employees walk near an Abbott Laboratories sign at the company's headquarters complex in Abbott Park, Illinois.

    Abbott Laboratories forecast full-year profit in line with analysts' estimates even as other drugmakers warned of a strong dollar hurting results.

  • Jan 29- Abbott Laboratories forecast full-year profit largely in line with analysts' estimates even as other large drugmakers have warned of a stronger dollar hurting their results. The company, which received more than 70 percent of revenue from outside the United States, said it expects 2015 earnings of $2.10- $2.20 per share, compared with the average...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Midday movers: Lands' End, Wynn Resorts, Exxon & more Wednesday, 10 Dec 2014 | 12:49 PM ET

    Some of Wednesday's midday movers:

  • Valeant to drop deal-making to cut debt, lift stock Tuesday, 9 Dec 2014 | 9:00 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Trader on the floor of the New York Stock Exchange.

    Some of Monday's midday movers: